Metraipolis › archive › dc_65482f39c0ae

CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients: a meta-analysis of… — Europe PMC PMID:42192452

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42192452
DOI
10.1186/s13058-[numero omesso]-x
License (as archived)
solo-consultazione
Archived
2026-11-01T06:41:05.266Z
SHA-256 of the archived text
905ca48adbc19974ead0cba5317299f7efb47731ccd04e930bfa03aa965ebbf7
Stable URL of this page
https://metraipolis.com/documento/dc_65482f39c0ae

How to cite

CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients: a meta-analysis of… — Europe PMC PMID:42192452 — Europe PMC (en), https://europepmc.org/article/MED/42192452 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_65482f39c0ae (Metraipolis archive dc_65482f39c0ae, sha256 905ca48adbc19974ead0cba5317299f7efb47731ccd04e930bfa03aa965ebbf7)
BibTeX
@misc{dc65482f39c0ae,
  title = {CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients: a meta-analysis of… — Europe PMC PMID:42192452},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42192452},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_65482f39c0ae; sha256 905ca48adbc19974ead0cba5317299f7efb47731ccd04e930bfa03aa965ebbf7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42192452. Agents can read the archived copy with the MCP tool read_document.